| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 106.37% | Morgan Stanley | $54 → $57 | Maintains | Overweight |
| 10/11/2023 | 95.51% | Morgan Stanley | $53 → $54 | Maintains | Overweight |
| 08/09/2023 | 91.89% | Morgan Stanley | $52 → $53 | Maintains | Overweight |
| 07/11/2023 | 88.27% | Morgan Stanley | $52 → $52 | Reiterates | Overweight → Overweight |
| 05/10/2023 | 88.27% | Morgan Stanley | $50 → $52 | Maintains | Overweight |
| 04/10/2023 | 81.03% | Morgan Stanley | $48 → $50 | Maintains | Overweight |
| 04/06/2023 | 117.23% | Tigress Financial | $57 → $60 | Reiterates | → Buy |
| 02/16/2023 | 73.79% | UBS | $51 → $48 | Maintains | Buy |
| 12/06/2022 | 84.65% | Morgan Stanley | $54 → $51 | Maintains | Overweight |
| 11/09/2022 | 95.51% | Morgan Stanley | $51 → $54 | Maintains | Overweight |
| 10/18/2022 | 88.27% | JP Morgan | $50 → $52 | Maintains | Overweight |
| 08/08/2022 | 84.65% | Morgan Stanley | $48 → $51 | Maintains | Overweight |
| 07/14/2022 | 106.37% | Tigress Financial | $52 → $57 | Maintains | Buy |
| 06/14/2022 | 70.17% | UBS | → $47 | Initiates Coverage On | → Buy |
| 05/13/2022 | 91.89% | Scotiabank | → $53 | Initiates Coverage On | → Outperform |
| 04/27/2022 | 102.75% | Goldman Sachs | → $56 | Initiates Coverage On | → Buy |
| 04/14/2022 | 81.03% | JP Morgan | → $50 | Upgrades | Neutral → Overweight |
| 04/06/2022 | 73.79% | Morgan Stanley | $46 → $48 | Upgrades | Equal-Weight → Overweight |
| 10/29/2021 | 81.03% | Citigroup | → $50 | Upgrades | Neutral → Buy |
| 08/16/2021 | 66.55% | Morgan Stanley | $51 → $46 | Maintains | Equal-Weight |
| 07/30/2021 | 81.03% | Tigress Financial | → $50 | Initiates Coverage On | → Buy |
| 11/09/2020 | 84.65% | UBS | → $51 | Upgrades | Neutral → Buy |
| 07/13/2020 | 81.03% | JP Morgan | → $50 | Initiates Coverage On | → Neutral |
| 07/13/2020 | 99.13% | B of A Securities | → $55 | Initiates Coverage On | → Buy |
| 07/13/2020 | 84.65% | Morgan Stanley | → $51 | Initiates Coverage On | → Equal-Weight |
| 07/13/2020 | 99.13% | Cowen & Co. | → $55 | Initiates Coverage On | → Outperform |
| 07/13/2020 | 102.75% | SunTrust Robinson Humphrey | → $56 | Initiates Coverage On | → Buy |
What is the target price for Royalty Pharma (RPRX)?
The latest price target for Royalty Pharma (NASDAQ: RPRX) was reported by Morgan Stanley on November 9, 2023. The analyst firm set a price target for $57.00 expecting RPRX to rise to within 12 months (a possible 106.37% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Royalty Pharma (RPRX)?
The latest analyst rating for Royalty Pharma (NASDAQ: RPRX) was provided by Morgan Stanley, and Royalty Pharma maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Royalty Pharma (RPRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Royalty Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Royalty Pharma was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Royalty Pharma (RPRX) correct?
While ratings are subjective and will change, the latest Royalty Pharma (RPRX) rating was a maintained with a price target of $54.00 to $57.00. The current price Royalty Pharma (RPRX) is trading at is $27.62, which is out of the analyst's predicted range.